CHUCK SODER - SPR Therapeutics will receive a $1.45 million grant that it will use to develop an implantable version of its nerve stimulation system, which is used to treat post-amputation pain. The Highland Hills-based company is in the process of testing a non-implantable version of its technology in clinical trials funded by a $2.8 million Department of Defense grant. However, the implantable version will allow SPR to treat patients who will need nerve stimulation for an extended period of time. The grant
↧